Elkana Kohn

Dr. Elkana Kohn

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2024 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Open access
GSGeorgios Schoretsanitis
Georgios Schoretsanitis
KDKristina Deligiannidis
Kristina Deligiannidis
NKNicholas Kasperk
Nicholas Kasperk
CSChiara Theresa Schmidt
Chiara Theresa Schmidt
SKSarah Kittel-Schneider
Sarah Kittel-Schneider
MPMichael Paulzen
Michael Paulzen
Increasing evidence suggests that the physiological changes of pregnancy may impact pharmacokinetics of antiseizure medications (ASM), and this may affect treatment outcomes. The aim of this study was to quantify the pregnancy impact on the ASM pharmacokinetics. A systematic literature search was conducted in PubMed/EMBASE in November 2022 and updated in August 2023 for studies comparing levels of ASM in the same individuals during pregnancy and in the preconception/postpartum period. Alteration ratios between the 3rd trimester and baseline were estimated. We also performed a random-effects meta-analysis calculating between-timepoint differences in mean differences (MDs) and 95% confidence intervals (95%CIs) for dose-adjusted plasma concentrations (C/D ratios). Study quality was assessed using the ClinPK guidelines. A total of 65 studies investigating 15 ASMs in 674 pregnancies were included. The largest differences were reported for lamotrigine, oxcarbazepine and levetiracetam (alteration ratio 0.42, range 0.07-2.45, 0.42, range 0.08-0.82 and 0.52, range 0.04-2.77 respectively): accordingly, C/D levels were lower in the 3rd trimester for lamotrigine, levetiracetam and the main oxcarbazepine metabolite monohydroxycarbazepine (MD = -12.33 × 10-3, 95%CI = -16.08 to -8.58 × 10-3 (μg/mL)/(mg/day), p < 0.001, MD = -7.16 (μg/mL)/(mg/day), 95%CI = -9.96 to -4.36, p < 0.001, and MD = -4.87 (μg/mL)/(mg/day), 95%CI = -9.39 to -0.35, p = 0.035, respectively), but not for oxcarbazepine (MD = 1.16 × 10-3 (μg/mL)/(mg/day), 95%CI = -2.55 to 0.24 × 10-3, p = 0.10). The quality of studies was acceptable with an average rating score of 11.5. Data for lamotrigine, oxcarbazepine (and monohydroxycarbazepine) and levetiracetam demonstrate major changes in pharmacokinetics during pregnancy, suggesting the importance of therapeutic drug monitoring to assist clinicians in optimizing treatment outcomes.

19 April 2023 in Children
Verified
Journal Article
Open access
PDF file
GSGal Shiloh
Gal Shiloh
EGEynat Gal
Eynat Gal
ADAyelet David
Ayelet David
EKElkana Kohn
Elkana Kohn
AHAriela Hazan
Ariela Hazan
OSOrit Stolar
Orit Stolar
Restricted and repetitive behaviors and interests (RRBI) are a significant component in diagnosing autism spectrum disorder (ASD). They often pose the main challenge in day-to-day functions for children with ASD and their families. Research addressing family accommodation behaviors (FAB) in the ASD population is scarce, and associations with the characteristics of the children’s behaviors are unclear. This sequential mixed-methods study assessed the correlation between RRBI and FAB within the ASD group to deepen the understanding of parents’ subjective experiences regarding their children’s RRBI. It included a quantitative phase with a follow-up qualitative study. A total of 29 parents of children with autism (5–13 yr) completed the study questionnaires; a total of 15 also were interviewed regarding their children’s RRBI and related FAB. We used the Repetitive Behavior Scale-Revised (RBS-R) to assess RRBI, and the Family Accommodation Scale (FAS-RRB) to assess FAS. In-depth interviews from phenomenological methodology were used in the qualitative phase. We found significant positive correlations between the RRBI and FAB overall and their subscores. Qualitative research supports these findings, adding descriptive examples of the accommodations families make to address the RRBI-related challenges. The results indicate relations between RRBI and FAB and the importance of practically addressing children with autism’s RRBI and their parents’ experiences. Both affect and are affected by the children’s behaviors.

1 February 2024 in Cannabis & Cannabinoid Research
Verified
Journal Article
Closed access
DBDana Barchel
Dana Barchel
OSOrit Stolar
Orit Stolar
TZTomer Ziv-Baran
Tomer Ziv-Baran
IGItai Gueta
Itai Gueta
MBMatitiahu Berkovitch
Matitiahu Berkovitch
LSLihi Bar-Lev Schleider
Lihi Bar-Lev Schleider
Objective: Tourette's syndrome (TS) is a neurodevelopmental disorder characterized by vocal and motor tics and other comorbidities. Clinical recommendations for the use of medical cannabis are established, yet further guidance is needed. The aim of this study was to describe the experience of patients with TS with medical cannabis. Materials and Methods: TS patients were recruited from a registry of patients (“Tikun Olam” company). Questionnaires were answered before and after 6 months of treatment. Patients were divided into two groups: (A) patients who responded and (B) patients who did not respond to the follow-up questionnaire. In group A, an analysis was made to evaluate the presence and frequency of motor and vocal tics. The patients' general mood, employment status, quality of life, and comorbidities were also included in the analysis. Results: Seventy patients were identified. The tetrahydrocannabinol and cannabidiol mean daily dose was 123 and 50.5 mg, respectively. In group A, a statistically significant improvement was identified in quality of life ( p <0.005), employment status ( p =0.027), and in the reduction of the number of medications ( p 0.999), tics frequency ( p =0.062), or general mood ( p =0.129). The most frequent adverse effects were dizziness ( n =4) and increased appetite ( n =3). Conclusion: Subjective reports from TS patients suggest that medical cannabis may improve their quality of life and comorbidities. More studies are needed to evaluate the efficacy and safety of medical cannabis. Registry in the MOH: https://www.moh.gov.sg/ (Trial number: 0185-19-ASF)

1 October 2020 in Reproductive Toxicology
Verified
Journal Article
Closed access
EKElkana Kohn
Elkana Kohn
NDNatalia Dinavitser
Natalia Dinavitser
RGRevital Gandelman-Marton
Revital Gandelman-Marton
MBMaya Berlin
Maya Berlin
AHAriella Hazan
Ariella Hazan
MBMatitiahu Berkovitch
Matitiahu Berkovitch

1 April 2022 in Breastfeeding Medicine
Verified
Journal Article
Closed access
EKElkana Kohn
Elkana Kohn
NDNatalie Dinavitser
Natalie Dinavitser
MBMaya Berlin
Maya Berlin
NBNurit Brandriss
Nurit Brandriss
ABAdina Bar-Chaim
Adina Bar-Chaim
MMMajdi Masarwi
Majdi Masarwi
Importance: Lamotrigine use during breastfeeding has significantly increased in the recent years, whereas breast milk lamotrigine pharmacokinetics data are still sparse. Objectives: To assess lamotrigine exposure in breastfed infants by monitoring maternal serum and breast milk concentrations. Methods: Breastfeeding women treated with lamotrigine were recruited to this study. Maternal trough breast milk and serum samples were collected, and additional breast milk samples were collected 1, 3, 6, 9, 12 hours after lamotrigine consumption. Trough breast milk/serum ratios (M/S ratio) and breast milk area under the curve (AUC) values were calculated. Results: Twenty-one breastfeeding women were recruited to this study, and the final dataset was based on the samples collected from 17 women. Lamotrigine trough serum and mother's milk concentrations were 5.1 ± 3.3 mg/L and 3.1 ± 1.9 mg/L, respectively (mean ± standard deviation). The trough M/S ratio of lamotrigine was 0.66 ± 0.22. The lamotrigine breast milk average AUC was 41.7 ± 24.6 mg·h/L. The estimated infant dose of lamotrigine was 0.52 ± 0.31 mg/kg/day and 0.26 ± 0.15 mg/kg/day for fully and partially breastfed infants, respectively. Significant correlation was found between the maternal lamotrigine serum trough concentrations and the breast milk parameters: trough breast milk concentrations (Spearman's rho = 0.986, p < 0.0001) and breast milk AUC values (Spearman's rho = 0.941, p < 0.0001). No significant correlation was found between the maternal lamotrigine daily dose and serum trough concentrations, breast milk trough concentrations, and breast milk AUC values (Spearman's rho = 0.294, 0.285, and 0.438, p = 0.252, 0.396, and 0.078, respectively). Conclusion and Relevance: High correlation between the maternal lamotrigine trough serum concentrations and the breast milk AUC values was found, implying that monitoring the maternal lamotrigine serum concentrations can be useful for prediction of exposure of infants to lamotrigine through the breast milk. The trial was registered in the Israeli trials registry MOH_2021-09-05_010243 at September 5, 2021 Retrospectively registered https://my.health.gov.il/CliniTrials

5 May 2026 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
LALeo Arkush
Leo Arkush
RKRinat Komargodski
Rinat Komargodski
HEHagar Bernad Elazari
Hagar Bernad Elazari
SUShimrit Uliel-Sibony
Shimrit Uliel-Sibony
VCVeronika Chernuha
Veronika Chernuha
MTMichal Tzadok
Michal Tzadok